https://pubmed.ncbi.nlm.nih.gov/36815351/
Reply: The mucosal gut signature in primary sclerosing cholangitis before and after liver transplantation. Is the dysbiosis index really predictive for the...
sclerosing cholangitisreplymucosalgutsignature
https://www.mayoclinic.org/diseases-conditions/primary-sclerosing-cholangitis/care-at-mayo-clinic/mac-20355806
Scarring in the bile ducts blocks the flow of bile from the liver and damages liver tissue. A liver transplant is the only known cure.
sclerosing cholangitismayo clinicprimarypsccare
https://www.mayoclinic.org/diseases-conditions/sclerosing-mesenteritis/care-at-mayo-clinic/mac-20355090
Sclerosing mesenteritis is a rare condition that may lead to blockage in the small intestine. Learn about treatment at Mayo Clinic.
sclerosing mesenteritismayo cliniccare
https://www.aapc.com/codes/icd-10-codes/H16.332
ICD-10 code H16.332 for Sclerosing keratitis, left eye is a medical classification as listed by WHO under the range -Disorders of sclera, cornea, iris
left eyeicdcodesclerosingkeratitis
https://www.pharmaceutical-technology.com/data-insights/hymecromone-halo-biosciences-primary-sclerosing-cholangitis-likelihood-of-approval/
Hymecromoneis under clinical development by Halo Biosciences and currently in Phase II for Primary Sclerosing Cholangitis.
sclerosing cholangitishymecromonehalobiosciencesprimary
https://www.marketresearchfuture.com/reports/primary-sclerosing-cholangitis-market-27093
Primary Sclerosing Cholangitis Market growth is projected to reach USD 0.27 Billion, at a 4.91% CAGR by driving industry size, share, top company analysis,...
sclerosing cholangitismarket growthprimaryreport
https://pubmed.ncbi.nlm.nih.gov/39679639/
Outcomes after retransplantation for PSC were similar or better compared to the comparison group. Retransplantation represents a treatment option with the...
sclerosing cholangitisoutcomeliverpatientsprimary
https://www.pharmaceutical-technology.com/data-insights/hpg-1860-hepagene-therapeutics-shanghai-primary-sclerosing-cholangitis-likelihood-of-approval/
HPG-1860 is under clinical development by Hepagene Therapeutics Shanghai and currently in Phase I for Primary Sclerosing Cholangitis.
sclerosing cholangitishpgtherapeuticsshanghaiprimary
https://www.academia.edu/81857383/Clinical_drug_resistant_nodular_sclerosing_Hodgkins_lymphoma_is_associated_with_decreased_bcl_2_expression_in_the_surrounding_lymphocytes_and_with_increased_bcl_2_expression_in_the_Reed_Sternberg_cells
Clinical drug-resistant nodular sclerosing Hodgkin's lymphoma is associated with decreased bcl-2 expression in the surrounding lymphocytes and with increased...
drug resistantpdfclinicalnodularsclerosing
https://pubmed.ncbi.nlm.nih.gov/28802875/
Primary sclerosing cholangitis (PSC) is a rare disorder characterised by multi-focal bile duct strictures and progressive liver disease. Inflammatory bowel...
sclerosing cholangitiscomprehensive reviewprimary